GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rennova Health Inc (OTCPK:RNVA) » Definitions » Forward Rate of Return (Yacktman) %

RNVA (Rennova Health) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Rennova Health Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Rennova Health's forward rate of return for was 0.00%.

The historical rank and industry rank for Rennova Health's Forward Rate of Return (Yacktman) % or its related term are showing as below:

RNVA's Forward Rate of Return (Yacktman) % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 7.23
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Rennova Health Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Rennova Health's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rennova Health Forward Rate of Return (Yacktman) % Chart

Rennova Health Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rennova Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rennova Health's Forward Rate of Return (Yacktman) %

For the Diagnostics & Research subindustry, Rennova Health's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rennova Health's Forward Rate of Return (Yacktman) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rennova Health's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Rennova Health's Forward Rate of Return (Yacktman) % falls into.


;
;

Rennova Health Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Rennova Health's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.0001+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rennova Health  (OTCPK:RNVA) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Rennova Health Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Rennova Health's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rennova Health Business Description

Traded in Other Exchanges
N/A
Address
477 S. Rosemary Avenue, Suite 800, West Palm Beach, FL, USA, 33401
Rennova Health Inc is a vertically integrated provider of healthcare-related products and services. The company operates through a single business segment namely the Hospital operations segment reflects the purchase of the hospital assets. Geographically, the activities are carried out throughout the region of the US.
Executives
Jonathan Immordino officer: Chief Financial Officer 3340, POSEIDON WAY, INDIALANTIC FL 32903
Marlene Mclennan officer: Chief Financial Officer 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Gary L Blum director 3278 WILSHIRE BOULEVARD, SUITE 603, LOS ANGELES, CALIFORNIA CA 90010
John Beach director 400 S. AUSTRALIAN AVENUE,, SUITE 800,, WEST PALM BEACH, FL 33401
Kamran Ajami director 3920 NW 43RD ST., COCONUT CREEK FL 33073
Trevor Langley director 1000 N. GREEN VALLEY PARKWAY, #440-420, HENDERSON NV 89074
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Sharon Lynne Hollis 10 percent owner 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Robert P Lee director 400 S. AUSTRALIAN AVE., #800, WEST PALM BEACH FL 33134
Aella, Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Epizon Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Michael Louis Goldberg director 2008 BAYVIEW DRIVE, FORT LAUDERDALE FL 33305
Benjamin Frank director 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Jason Adams officer: Chief Financial Officer 4700 SANTA DEL RAE AVENUE, FT MYERS FL 33901
George Lundberg officer: Editor in Chief and CMO 44 MONTGOMERY STREET, SUITE 800, SAN FRANCISCO CA 94104